Patrizia Perri

List of Publications by Year in descending order

58 papers	2,990 citations	236612 25 h-index	189595 50 g-index
58 all docs	58 docs citations	58 times ranked	4857 citing authors

#	Article	IF	Citations
1	MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway. Pharmaceuticals, 2022, 15, 297.	1.7	10
2	Recent advances in the developmental origin of neuroblastoma: an overview. Journal of Experimental and Clinical Cancer Research, 2022, 41, 92.	3.5	46
3	Metastatic progression in infants diagnosed with stage 4S neuroblastoma. A study of the Italian Neuroblastoma Registry. Pediatric Blood and Cancer, 2021, 68, e28904.	0.8	3
4	Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 107.	1.1	7
5	Bone Marrow Environment in Metastatic Neuroblastoma. Cancers, 2021, 13, 2467.	1.7	5
6	Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 180.	3.5	27
7	The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis. Nutrients, 2021, 13, 2178.	1.7	15
8	Cotargeting of miRâ€126â€3p and miRâ€221â€3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling. Molecular Oncology, 2021, 15, 2969-2988.	2.1	16
9	Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors. Pharmaceuticals, 2021, 14, 854.	1.7	8
10	A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma. Cancers, 2021, 13, 5528.	1.7	16
11	Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. Cancers, 2020, 12, 1468.	1.7	14
12	Combined Replenishment of miRâ€34a and letâ€7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. Small, 2020, 16, e1906426.	5.2	27
13	Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. Journal of Controlled Release, 2019, 308, 44-56.	4.8	41
14	Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers. Small, 2019, 15, e1804591.	5.2	34
15	Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy. , 2019, , .		0
16	Enhancement of Tumor Homing by Chemotherapyâ€Loaded Nanoparticles. Small, 2018, 14, e1802886.	5.2	23
17	Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer. International Journal of Molecular Sciences, 2018, 19, 1953.	1.8	117
18	Abstract 3879: Enhancement of tumor penetration by drug-loaded nanoparticles: An innovative targeted strategy for neuroblastoma. , 2018, , .		0

#	Article	IF	Citations
19	A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. Molecular Therapy, 2017, 25, 218-231.	3.7	65
20	Abstract 5130: Tumor-penetrating peptide-coated nanoparticles as a novel strategy for the targeted therapy of neuroblastoma. , 2017, , .		0
21	A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. Journal of Hepatology, 2016, 65, 75-83.	1.8	15
22	A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects. Journal of Controlled Release, 2016, 223, 165-177.	4.8	89
23	Abstract 3844: A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. , 2016, , .		0
24	New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. Oncotarget, 2015, 6, 28774-28789.	0.8	18
25	Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. Biomaterials, 2015, 68, 89-99.	5.7	36
26	Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. Journal of Controlled Release, 2015, 211, 44-52.	4.8	49
27	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Science Translational Medicine, 2015, 7, 283ra55.	5.8	120
28	Quiescent Hepatic Stellate Cells Functionally Contribute to the Hepatic Innate Immune Response via TLR3. PLoS ONE, 2014, 9, e83391.	1.1	26
29	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. Cancer Research, 2014, 74, 6094-6106.	0.4	45
30	sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib. Journal of Controlled Release, 2014, 192, 157-166.	4.8	26
31	Abstract 2622: New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs againstALK. , 2014, , .		0
32	Abstract 1453: MicroRNA replacement and RNAi-mediated silencing of ALK as combined targeted therapies for neuroblastoma. Cancer Research, 2014, 74, 1453-1453.	0.4	1
33	Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity. European Journal of Cancer, 2013, 49, 3353-3365.	1.3	32
34	Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. Journal of Controlled Release, 2013, 170, 445-451.	4.8	41
35	Nanocarrier-Mediated Targeting of Tumor and Tumor Vascular Cells Improves Uptake and Penetration of Drugs into Neuroblastoma. Frontiers in Oncology, 2013, 3, 190.	1.3	21
36	The use of the orthotopic model to validate antivascular therapies for cancer. International Journal of Developmental Biology, 2011, 55, 547-555.	0.3	43

#	Article	IF	Citations
37	Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK. Molecular Therapy, 2011, 19, 1131-1140.	3.7	56
38	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. Molecular Therapy, 2011, 19, 2201-2212.	3.7	57
39	Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Journal of Controlled Release, 2010, 145, 66-73.	4.8	78
40	PHOX2B-Mediated Regulation of ALK Expression: In Vitro Identification of a Functional Relationship between Two Genes Involved in Neuroblastoma. PLoS ONE, 2010, 5, e13108.	1.1	40
41	Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma. Cancer Research, 2010, 70, 9816-9826.	0.4	65
42	Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model. Current Drug Targets, 2009, 10, 1021-1027.	1.0	14
43	Abstract A130: Effects of a novel liposomal formulation of fenretinide on human neuroblastoma cell growth, apoptosis and angiogenesis. , 2009, , .		0
44	Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008, 455, 930-935.	13.7	1,207
45	Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis. Clinical Cancer Research, 2007, 13, 3977-3988.	3.2	77
46	Genetic Predisposition to Familial Neuroblastoma: Identification of Two Novel Genomic Regions at 2p and 12p. Human Heredity, 2007, 63, 205-211.	0.4	34
47	Concomitant DDX1 and MYCN gain in neuroblastoma. Cancer Letters, 2007, 256, 56-63.	3.2	8
48	PHOX2B mutations and genetic predisposition to neuroblastoma. Oncogene, 2005, 24, 3050-3053.	2.6	45
49	Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. Journal of Pathology, 2005, 207, 346-357.	2.1	36
50	Oligogenic inheritance in neuroblastoma. Cancer Letters, 2005, 228, 65-69.	3.2	15
51	Familial neuroblastoma: a complex heritable disease. Cancer Letters, 2003, 197, 41-45.	3.2	24
52	Weak linkage at 4p16 to predisposition for human neuroblastoma. Oncogene, 2002, 21, 8356-8360.	2.6	40
53	Linkage Analysis in Families with Recurrent Neuroblastoma. Annals of the New York Academy of Sciences, 2002, 963, 74-84.	1.8	17
54	Restriction fragment length polymorphism analysis reveals different allele frequency and a linkage disequilibrium at locus D1S94 in neuroblastoma patients. European Journal of Cancer, 1997, 33, 1949-1952.	1.3	3

#	Article	IF	Citations
55	MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.. Journal of Clinical Oncology, 1997, 15, 85-93.	0.8	111
56	N-myc amplification and cell proliferation rate in human neuroblastoma. , 1997, 183, 339-344.		15
57	Peculiar allelotype associated with susceptibility to neuroblastoma. , 1996, 17, 60-63.		4
58	PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. International Journal of Oncology, 1992, 33, 985.	1.4	8